It has been reported that BM is more frequent in patients with tumors harboring EGFR mutations; NSCLC patients with tumors harboring exon 19 deletions showed a higher incidence of central nervous system involvement compared with those with tumors harboring the L858R mutation 25-27. This evidence concerns the gene EGFR and non-small cell lung carcinoma.